GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Allergenextrakt aus Wiesenlieschgras, Ruchgras, etc. (ausschl. SUT), ATC V01AA02 f. d. Z. 01.10.24-30.09.26

Health · Germany government procurement

Closed August 05, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$1
Est. Value
Closed
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient allergen extract from timothy grass, sweet vernal grass, etc. (excl. SUT), ATC V01AA02, valid from 01.10.24 to 30.09.26

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
Estimated value$1
PublishedAugust 19, 2024
Procurement stageActive solicitation
ClosedAugust 05, 2026
StatusClosed — no longer accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 09, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ustekinumab, (OBG) ATC L04AC05 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Prednisolon, ATC S01BA04 für die Zeit 01.02.2026 - 31.01.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Apremilast, (OBO) ATC L04AA32 für die Zeit 01.01.2025 - 31.12.2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol + Aclidiniumbromid, ATC R03AL05 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sevelamer hydrochlorid, (OBG) ATC V03AE02 für die Zeit 01.01.2025 - 31.12.2026
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient dolutegravir + rilpivirine, ATC J05AR21, for the period 01.07.2025 - 30.06.2027
Germany – Pharmaceutical products – Kontrastmittel - Wirkstoffübergreifendes Open-House-Verfahren für die KV-Region Westfalen-Lippe
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Epinephrin, ATC C01CA24 für die Zeit 01.07.2025 - 30.06.2027 (zzgl. Verlängerungsoption 1x12 Monate)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.